Recent seminal work by the Mole group has demonstrated the importance of the kynurenine pathway, downstream of IDO, in the development of AP both in patient and animal studies and is considered a promising therapeutic target [17,18]. Here, IDO1 is linked to alkaline phosphatase measurement.